When combined with novel indices like the Advanced Lung Cancer Inflammation Index (ALI), which integrates albumin and neutrophil-to-lymphocyte ratio, assessment of patient risk can be substantially enhanced without the need for complex or costly tools [40]. The gene discussed is ALB; the disease is lung cancer.